A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

DOI: 10.1080/2162402X.2018.1507262

Keywords: Neutrophil-to-lymphocyte ratio, Nivolumab, immunotherapy, lung cancer, meta-analysis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text